What Tools Were Used in the Studies for Lambert-Eaton Myasthenic Syndrome (LEMS)? Before describing how Firdapse was studied, it is important to understand the tools that were used in the studies.

Angelini Pharma has entered a definitive agreement to acquire Catalyst Pharmaceuticals (NasdaqCM:CPRX). The deal marks Angelini Pharma's planned entry into the U.S. market focused on brain health and ...

Catalyst Pharmaceuticals, Inc.’s CPRX lead drug, Firdapse (amifampridine), is approved in the United States and Europe for the treatment of adult patients with Lambert-Eaton myasthenic syndrome (“LEMS ...

As Part of the Settlement, Hetero Labs Ltd. Receives a License to Market Generic FIRDAPSE Beginning in January 2035 Catalyst has No Other FIRDAPSE Patent Litigation Pending CORAL GABLES, Fla., May 07, ...

Dublin, Dec. 30, 2020 (GLOBE NEWSWIRE) -- The "Firdapse (Amifampridine) - Drug Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. Firdapse (amifampridine) ...

New York, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Firdapse (amifampridine) - Drug Insight and Market Forecast - 2030 ...

Catalyst Pharmaceuticals' Q1 2026 revenue surged as Firdapse and Agamree drove growth; Angelini’s $31.50 offer limits upside.

The FDA’s 2019 approval of Jacobus Pharmaceutical Co. Inc.’s Ruzurgi to treat children ages 6 to 17 with Lambert-Eaton myasthenic syndrome must be set aside because it violated the Orphan Drug Act in ...

- Firdapse 2019 Net Product Revenues Expected to be Approximately $102 Million -Anticipates Full Year 2020 Firdapse Net Product Revenues to be in the Range of $135 million to $155 million - MuSK-MG ...

We issued an updated research report on Catalyst Pharmaceuticals Inc. CPRX on Sep 7, 2020. Catalyst’s share price has declined 17.9% compared with the industry’s decline of 9% in the year so far. The ...

Catalyst, a commercial-stage biopharmaceutical company focused on in-licensing, developing and commercializing novel medicines, announced that the company and its licensor SERB have entered into an ...